Search PubMed⌕ Search

Biomedical subjects

K Aso

Publications and source records attributed to K Aso.

At least 163 records · Page 9Linked to original sources
PubMed1983

[Laboratory and clinical studies of T-1982 (cefbuperazone) in pediatric infectious diseases].

Laboratory and clinical studies were carried out with T-1982 (cefbuperazone) in pediatric infectious diseases. Results were as follows. 1. The average serum concentrations of T-1982 following intravenous injection of 10 mg/kg and 20 mg/kg were 35.3, 64.7 micrograms/ml at 30 minutes, 25.5, 41.5 micrograms/ml at 1 hour, 12.4, 21.8 micrograms/ml at 2 hours, respectively. Dose-response was observed. Urinary recovery rates of T-1982 during 6 hours after injection of 10 mg/kg and 20 mg/kg were 57.3% and 73.6%, respectively. 2. The antibacterial activity of T-1982 against clinically isolated organisms was determined. T-1982 was more active than cefazolin and cefmetazole against K. pneumoniae, H. influenzae and E. coli. It was also effective against ampicillin-resistant E. coli. 3. Thirty-seven patients received daily 30-69 mg/kg of T-1982 t.i.d. for 5-9 days. The rate of satisfactory clinical response was 91.9%. 4. Side effects were diarrhea in 4 cases, diarrhea and rash in 1 case and slight elevation of GOT and GPT in 1 case. But these were transient and mild.

Anti-Bacterial Agents↗
PubMed1983

[Evaluation of cefotetan in pediatrics].

Clinical trials were carried out with cefotetan (CTT) in pediatric infections. Results were as follows; The mean serum concentrations of CTT following intravenous injection of 20 mg/kg were 204, 97, 56, 15, 10 micrograms/ml at 15, 60, 120, 360, 480 minutes after injection. The serum half-life was 2.18 hours. 68.3% was excreted in urine within 8 hours after injection. In vitro, the antimicrobial activity of CTT was more active than CEZ and CMZ against E. coli, H. influenzae and K. pneumoniae. CTT was administered clinically to 22 pediatric patients with various infections; 9 pneumonias, 4 bronchopneumonias, 1 acute tonsillitis and 8 urinary tract infections. Overall efficacy rate was 95%. The favorable clinical response could be gained by the doses of 30 mg/kg with being given every 12 hours. Slight elevation of S-GOT and S-GPT with mild diarrhea was observed in 2 patients and eosinophilia in 1 patient. No other serious side effect was observed.

Age Factors↗
PubMed1983

Utilization of the extensor retinaculum in the radiocarpal joint of rheumatoid wrists.

Synovectomy and debridement were combined with use of pedicled flaps of the extensor retinaculum as interposition material in the radiocarpal joint to cover the eroded articular surfaces of the radius and ulna in rheumatoid wrists. The technique was devised for the purpose of preventing postoperative osseous ankylosis of the radiocarpal joint. Results were satisfactory in 13 of 17 wrists operated on during the period from 1974 to 1979 and followed up for 38 to 84 months (average, 61 months).

Adult↗
PubMed1983

[Clinical evaluation of an ampicillin suppository (KS-R1) in infections in children].

The following results were obtained in clinical trials of new ampicillin suppository (KS-R1) in the pediatric infection. Twenty-four patients comprising 15 with respiratory tract infection, 9 with urinary tract infection were received KS-R1 at the dose ranging from 31 mg/kg to 75 mg/kg divided 3 or 4 times a day. The results in the respiratory tract infection were "excellent" in 8 and "good" in 6, and the efficacy rate was 93.3%. The results in the urinary tract infection were "excellent" in 4 and "good" in 3, and the efficacy rate was 77.8%. Diarrhea were observed in 4 patients, and anal pain was observed in 1. But the symptoms were transient. No abnormal laboratory findings were observed.

Age Factors↗
PubMed1983

[Evaluation of cefpiramide in pediatrics].

Fundamental and clinical trials were carried out with cefpiramide (CPM) in pediatric infections. Results were as follows. CPM has a broad spectrum of activity against both Gram-positive and -negative microorganisms, including Pseudomonas. Half-lives of CPM were more prolonged than any others that have ever been reported on cephalosporin derivatives. The mean half-lives in the blood after infection were 4.76 hours and 4.14 hours, when the doses were 10 mg/kg and 20 mg/kg, respectively. The average recovery rates in the urine between 0 and 8 hours were 17.1% and 24.7%, when the intravenous doses were 10 mg/kg and 20 mg/kg, respectively. Thirty-two pediatric patients received CPM in doses ranging from 31.9 to 88.2 mg/kg divided mainly 2 times a day. They were respiratory tract infection in 23, urinary tract infection in 8, and SSSS in 1. The rate of satisfactory clinical response was 90.6%. Clinical side effect observed were mild diarrhea in 7 cases. Slight elevation of GOT and GPT were observed in 3 cases. All were considered to be minor.

Adolescent↗
PubMed1982

[Fundamental and clinical studies of ceftizoxime in pediatric infections (author's transl)].

Experimental and clinical trials were carried out with ceftizoxime in pediatric infections. Results were as follows. 1. The antibacterial activity of ceftizoxime against clinically isolated organisms was determined. Ceftizoxime was more active than cefazolin, cefotiam and cefmetazole against K. pneumoniae, E. coli and H. influenzae. 2. The serum concentrations of ceftizoxime following intravenous injection of 10 mg/kg were 16.2, 10.1, 6.2, 1.8 micrograms/ml at 30, 60, 120, 240 minutes after injection, respectively. Ceftizoxime was excreted with the rate of 97.2% in the 6-hour urine after injection. 3. Twenty-one patients comprising 5 with urinary tract infection, 16 with respiratory tract infection were received ceftizoxime at the doses ranging from 32 to 109 mg/kg divided 3 or 4 times a day. The results were excellent in 8 and good in 13 patients. The rate of satisfactory clinical response was 100%. 4. Slight and transient elevation of GPT was observed in 1 patient. Other side effects were not observed in any of these 21 patients.

Age Factors↗
PubMed1982

[Laboratory and clinical studies of cefmenoxime in pediatric infections].

The antimicrobial activity of cefmenoxime (CMX) against clinical isolated organisms was measured; CMX was more active than cefotiam and cefazolin against Escherichia coli and Haemophilus influenzae. The serum concentrations of CMX following intravenous injection of 20 mg/kg were 25.6, 10.3, 3.0 micrograms/ml at 30, 60, 120 minutes after injection, respectively. CMX was excreted 60.9% in urine within 6 hours after injection. CMX was administered clinically to 22 pediatric patients with various infections (respiratory tract infection 16 including 1 pyothorax, urinary tract infection 4, tonsillitis with sinusitis 2) at the dose of 39 approximately 96 mg/kg/day for 4 approximately 9 days, and the following satisfactory results were obtained; excellent in 11, good in 9, and poor in 2. The rate of satisfactory clinical response was 90.9%. Eosinophilia 2 cases, slight elevation of transaminase 3 cases, slight elevation of BUN 1 case and transient diarrhea 1 case were observed. But no other serious side effects were observed.

Cefmenoxime↗
PubMed1981

Establishment of a cell line of human skin squamous cell carcinoma in vitro.

A cell line of a squamous cell carcinoma of human skin (HSC-I) has been established in vitro, and successfully maintained proliferative in continuous tissue culture for about 2 1/2 years since March 1978. Another cell line (HSC-Ib) has been established in vitro from the recurrence of the same cancer. It has been maintained for about 8 months since December 1979. 3T3 feeders were used in the initial cultures in both cases. The cells grow in a monolayer in vitro and are epithelioid with anaplastic features. Chromosome analysis of HSC-I, frozen and thawed HSC-I, the transplanted tumour in a nude mouse and HSC-Ib all showed hypotetraploidy with the modal number 80, which reconfirms that HSC-I derives from the original skin tumour. The cell line is available to other investigators.

Aged↗
PubMed1981

[Laboratory and clinical studies of cefoxitin in pediatric infections (author's transl)].

The antimicrobial activity of cefoxitin against clinical isolated organisms was measured: Cefoxitin was more active than cefazolin and cephalothin against Escherichia coli. The serum concentrations of cefoxitin following intravenous injection of 25 mg/kg were 267.7, 38.8, 8.3 microgram/ml at 5, 30, 120 minutes after injection, respectively. Cefoxitin was excreted 90.5% in urine within 6 hours after injection. Cefoxitin was administered clinically to 22 pediatric patients with various infections (urinary tract infection 9, respiratory tract infection 10, S.S.S.S. 1, Salmonella enteritis 1, and cervical lymphadenitis 1) at the dose of 45-98 mg/kg/day for 4-10 days, and the following satisfactory results were obtained; excellent in 16, good in 5, and poor in 1. The rate of satisfactory clinical response was 95.5%. Slight elevation of transaminase and A1-P were observed in 4 patients, but no other serious side effects were observed.

Adolescent↗